Julie D. Klapstein - 02 May 2023 Form 4 Insider Report for Oak Street Health, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 02 May 2023
Net transaction value: -$1,235,676
SEC form: 4
Accepted by SEC: 02 May 2023, 19:53:32 UTC
Prior SEC filing: 28 Apr 2023
Next SEC filing: 05 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Robert Guenthner, attorney-in-fact for Julie Klapstein

Key filing fact

Julie D. Klapstein filed Form 4 for Oak Street Health, Inc. on 02 May 2023.

Key facts

This page summarizes Julie D. Klapstein's Form 4 filing for Oak Street Health, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 May 2023, 19:53.

Change

Previous filing in this sequence was filed on 28 Apr 2023.
Current net transaction value: -$1,235,676.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OSH transaction

Common stock, $0.001 par value

Disposed to Issuer

Transaction value: $1,235,676
Shares: -31,684
Change %: -100%
Price: $39.00
Shares after: 0
Date: 02 May 2023
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Julie D. Klapstein is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to that certain Agreement and Plan of Merger, dated as of February 7, 2023 (the "Merger Agreement"), by and among the Issuer, CVS Pharmacy, Inc. ("Parent"), Halo Merger Sub Corp. ("Merger Sub") and, for the limited purposes set forth therein, CVS Health Corporation, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $39.00 per share in cash, without interest and subject to applicable tax withholdings (the "Per Share Price").

Footnote F2

(Continued from Footnote 1) The shares of the Issuer's common stock reported as disposed by the Reporting Person include vested restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically canceled and converted into the right to receive an amount in cash (without interest and subject to applicable tax withholdings) equal to the product of the Per Share Price multiplied by the number of shares of the Issuer's common stock subject to such RSUs as of immediately prior to the Effective Time.

Footnote F3

The shares of the Issuer's common stock reported as disposed on this Form 4 reflects a correction to the Reporting Person's Form 4 filed on April 25, 2023, which incorrectly reported 50,912 shares of the Issuer's common stock as beneficially owned by the Reporting Person following the reported transaction instead of the correct amount of 31,684 shares of the Issuer's common stock.